Replies to post #9387 on Momenta Pharmaceuticals, Inc. (MNTA)

[jbog]

Sandoz continued to strengthen its number one global position in biosimilars (USD 84 million, +28%, +39% cc), and saw strong momentum across all three of its products – Omnitrope (human growth hormone), Binocrit (epoetin alfa) and Zarzio (filgrastim) – each of which is the leading biosimilar in its respective market segment.

Doesn't $84 mil/q seem like a non event at this point?

[pollyvonwog]

NVS reports generic Lovenox® @ USD 156 million. A little less than 12% decline. Could have been worse.

I agree. More than I expected. If they keep that up without any changes to the lawsuit, the max MNTA will be burning a Q will then be around $15m (if they hit the high end of Shea's burn rate), which isn't so bad over the next few years.

[DewDiligence]

NVS’ 3Q12 sales of generic Lovenox shrank drastically to $34M (from $156M in 2Q12) due to increased competition and consequent pricing erosion. In 2Q12, WPI/Amphastar had their generic product on the market for only part of the quarter (after the preliminary injunction was stayed by the Appellate Court in late January).

In today’s press release re 3Q12, NVS cited “aggressive competitor pricing on enoxaparin” (http://www.sec.gov/Archives/edgar/data/1114448/000137036812000077/a121025-99_2.htm page 14).